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Abstract
Background: Delirium is a common occurrence in patients undergoing major cardiac surgery and is associated
with a number of adverse consequences for the individual, their family and the health system. Current approaches
to the prevention of delirium include identifying those at risk together with various non-pharmacological and
pharmacological strategies, although the efficacy of these is often modest. Emerging evidence suggests that
melatonin may be biologically implicated in the development of delirium and that melatonin supplementation may
be beneficial in reducing the incidence of delirium in medical and surgical patients. We designed this trial to
determine whether melatonin reduces the incidence of delirium following cardiac surgery compared with placebo.
Methods/Design: The Healthy Heart-Mind trial is a randomized, double-blind, placebo-controlled clinical trial of
3 mg melatonin or matching placebo administered on seven consecutive days for the prevention of delirium
following cardiac surgery. We will recruit 210 adult participants, aged 50 and older, undergoing elective or semi-
elective cardiac surgery with the primary outcome of interest for this study being the difference in the incidence of
delirium between the groups within 7 days of surgery. Secondary outcomes of interest include the difference
between groups in the severity and duration of delirious episodes, hospital length of stay and referrals to mental
health services during admission. In addition, we will assess differences in depressive and anxiety symptoms, as well
as cognitive performance, at discharge and 3 months after surgery.
Discussion: The results of this trial will clarify whether melatonin reduces the incidence of delirium following
cardiac surgery.
Trial registration: The trial is registered with the Australian Clinical Trials Registry, trial number
ACTRN12615000819527 (10 August 2015).
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Background
Delirium is a syndrome characterized by cognitive im-
pairment and attention deficits that usually develop over
a short period of time and fluctuate in intensity and
presentation. Several behavioral and psychological symp-
toms can accompany delirium, such as agitation, psych-
osis, disturbed sleep and mood changes, all of which can
cause distress to patients, their families and medical staff
[1]. Delirium has a prevalence of 15 % among hospital-
ized older adults [2], although it goes unrecognized in
32–66 % of them [3]. Delirium is particularly common
after surgery and is estimated to occur in up to 42 % of
patients undergoing major cardiac procedures [4–7].
Delirium is associated with poor clinical outcomes, in-
cluding higher risk of dementia and admission to resi-
dential care, as well as increased mortality [8]. Delirious
patients experience more postoperative complications
[4], higher readmission rates, poorer functional out-
comes [9], and increased length of stay [10]. The annual
cost of delirium to the health care system in the United
States is estimated to fall between US$38 billion and
US$152 billion [11]. Delirium may persist for several
weeks in up to a third of patients, leading to further in-
creased morbidity and mortality [12].
Postoperative cognitive decline following cardiac sur-
gery is estimated to occur in 24 to 79 % of patients and
persistence of symptoms is common [13]. Newman and
colleagues followed 261 patients for 5 years after coron-
ary artery bypass grafting (CABG) surgery [14]. They
found that 53 % of participants exhibited cognitive decline
at discharge, and although this proportion decreased at
the 6-month follow-up (24 %), the prevalence rose again
after 5 years to 42 %. These findings are consistent with
the possibility that postoperative cognitive dysfunction (of
which delirium is an important contributing factor)
worsens long-term cognitive outcomes [15].
Various factors increase the risk of delirium, including
age, pre-existing cognitive impairment, disruption of the
circadian rhythm, dehydration, malnutrition, and certain
medications [16]. Major cardiac surgery increases the
risk of delirium, with critical contributing factors includ-
ing the type of surgery, use of hemofiltration, medica-
tions administered, length of surgery, time on bypass,
high transfusion requirement, postoperative hyperten-
sion, patient’s age and whether the surgery was elective
[7]. Some of these risk factors are amenable to change,
whilst others (e.g., age) are not.
Current approaches to the prevention of delirium in hos-
pitalized patients consist of both non-pharmacological and
pharmacological approaches, of which the former are argu-
ably more effective [17]. Non-pharmacological approaches
involve addressing multiple risk factors in a systematic
manner together with education and environmental ma-
nipulation, although only relatively modest reductions in
delirium incidence are usually attainable [18]. Pharmaco-
logical approaches may include treatment with anti-
psychotic drugs, cholinesterase inhibitors, hypnotics, anti-
inflammatory drugs and gabapentin [19], but supportive
evidence of efficacy is not compelling. In addition, all of
these agents carry a relatively high risk of adverse effects.
Evidence linking melatonin and delirium
Melatonin is a serotonin-derived hormone secreted by
the pineal gland. It plays a pivotal role in the regulation
of the sleep-wake cycle [20], and has numerous other
biological and physiological functions. One of the typical
features of delirium is the disruption of the sleep-wake
cycle and circadian rhythm [1]. This raises the possibility
that melatonin-related pathways may mediate the ex-
pression of delirium [21]. In addition, older people are
more prone to sleep disorders arising from degeneration
of suprachiasmatic nuclei and resulting lower melatonin
levels [22]. Serum melatonin levels decrease post surgery
[23] and after the administration of certain opioids [24],
possibly contributing to the disrupted sleep-wake cycle
and increased risk of delirium that these patients experi-
ence. Plasma melatonin levels have been shown to be
lower in delirious patients following major surgery [25]
and urine concentrations of melatonin metabolites are
altered in people who are delirious [26]. It is also pos-
sible that melatonin demand is higher after surgery,
thereby leading to a relative depletion and greater risk of
delirium [27].
Melatonin secretion is stimulated by low exposure to
light and peak production corresponds to the main sleep
period in humans. Melatonin is metabolized in the liver
and excreted by the kidneys and has a short half-life
(40–50 minutes) [28]. The safety profile of melatonin in
clinical trials is comparable to placebo [29].
Existing preliminary data suggest that melatonin might
prevent and treat delirium
Four clinical trials of melatonin or melatonin agonists
for the prevention of delirium have been performed to
date (summarized in Fig. 1), although none of these have
been conducted in cardiac surgery patients. The earliest
of these enrolled 300 patients undergoing hip arthro-
plasty under spinal anesthesia [30]. Participants were
randomly allocated to one of four groups: control, mela-
tonin 5 mg, clonidine and, lastly, a group given midazo-
lam. The melatonin group received one dose in the
evening prior to surgery and 90 minutes pre-operatively.
The author reported a significant decrease in the preva-
lence of postoperative delirium in the melatonin group
compared with placebo (9.4 % versus 32.7 %, p = 0.003;
numbers needed to treat (NNT) = 5). Moreover, treat-
ment with melatonin was associated with remission of
delirium in 58.1 % of postoperative patients.
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In a trial of acutely ill medical in-patients aged 65 and
older, Al-Aama and colleagues randomly allocated 72
patients to melatonin and 73 to placebo [31]. Patients
consumed 0.5 mg of melatonin or placebo every night
for 14 days, or until discharge. Delirium was diagnosed
according to the Confusion Assessment Method (CAM)
[32]. Melatonin use was associated with a lower risk of
delirium (12 % versus 31 %, p = 0.014; NNT = 6), with an
odds ratio (OR) adjusted for dementia and comorbidities
of 0.19 (95 % CI 0.06 to 0.62). These differences
remained significant when patients with prevalent delir-
ium on admission were excluded (19.2 % in the placebo
and 3.6 % in the melatonin group, p < 0.02).
More recently de Jonghe and colleagues completed a
multicenter, placebo-controlled clinical trial in 378 pa-
tients undergoing hip surgery [33]. Participants received
3 mg of melatonin for 5 days starting within 24 hours of
admission. The authors found no difference in the inci-
dence of delirium between the melatonin (55/186,
29.6 %) and placebo (49/192, 25.5 %) groups (difference
4.1 %, 95 % CI −0.05 to 13.1), but reported that a smaller
proportion of participants in the melatonin group experi-
enced a long-lasting episode of delirium (>2 days) (25.5 %
versus 46.9 %, p = 0.02). Lastly, Hatta and colleagues con-
ducted a small trial of the melatonin agonist, ramelteon
(8 mg per day for 7 days) in 67 acutely unwell medical pa-
tients [34]. They reported a significant decrease in the inci-
dence of delirium in those taking ramelteon as compared
to placebo (3 % versus 32 %, p = 0.003; NNT= 4). The for-
est plot presented in Fig. 1 summarizes the efficacy data of
these trials.
The results of these trials suggest a potential role for
melatonin in preventing and treating delirium in older
adults, although conflicting results, methodological is-
sues (e.g., absence of a placebo-control group) and dif-
fering patient populations prevent firm conclusions from
being drawn and generalized.
Rationale for the proposed study
Delirium is frequent after cardiac surgery and is associated
with many adverse consequences. Emerging evidence sug-
gests that melatonin may be biologically implicated in the
development of delirium and that melatonin use may be
beneficial in reducing the incidence of delirium in medical
and surgical patients, but these results require replication
in differing at-risk populations.
Objectives
The primary outcome of interest for this study is the dif-
ference in the incidence of delirium (as determined by
the CAM and Diagnostic and Statistical Manual of
Mental Disorders, version 5 (DSM-5) criteria) between
the placebo and melatonin groups within 7 days follow-
ing cardiac surgery. Secondary outcomes of interest in-
clude the difference between groups in the severity and
duration of delirious episodes, hospital length of stay
and referrals to mental health services during the admis-
sion. In addition, we will assess for differences in mood
and anxiety symptoms and cognitive performance at dis-
charge and at 3 months after surgery.
Trial design
The Healthy Heart-Mind trial is a randomized, double-
blind, placebo-controlled clinical trial of 3 mg melatonin
or matching placebo administered on seven consecutive
days for the prevention of delirium following cardiac
surgery (two arms, 1:1 allocation, parallel design). This
study follows SPIRIT guidelines, and the relevant check-




We will recruit 210 participants undergoing elective or
semi-elective cardiac surgery in Perth, Western Australia.
All outpatients undergoing elective cardiac surgery attend
the pre-assessment clinics before admission (usually a
week prior). Potential participants will be approached dur-
ing this clinical review and offered an opportunity to par-
ticipate in the study. In addition, we will approach
patients admitted to cardiology and general hospital wards
awaiting surgery on a semi-elective basis; e.g., stable pa-
tients admitted with a myocardial infarction or unstable
angina deemed suitable for surgical intervention.
Fig. 1 Meta-analysis of available clinical trials. Forest plot showing the published clinical trials of melatonin for the prevention of delirium (primary
outcome of incident delirium). The meta-analysis shows a slight benefit for melatonin over placebo although small sample size and study heterogeneity
prevents firm conclusions from being drawn
Ford et al. Trials  (2016) 17:55 Page 3 of 8
Eligibility criteria
Participants will be:
1. Aged 50 years and older
2. Undergoing elective or semi-elective cardiac surgery
(on or off cardiopulmonary bypass) for coronary ar-
tery bypass grafting (CABG) and/or valvular surgery
We will exclude participants who:
1. Decline or are unable to give informed consent
2. Are undergoing emergency surgery
3. Are not fluent in written or spoken English (for the
purposes of being able to complete the study
assessments and questionnaires)
4. Have a contraindication to taking melatonin, such as
a prior allergic reaction
5. Are currently using melatonin
6. Have a diagnosis of dementia or score ≤19 on the
Telephone Interview for Cognitive Status-modified
(TICS-m) [35]
7. Have a score ≥15 on the Alcohol Use Disorders
Identification Test (AUDIT) [36]
Interventions
Eligible participants will be randomly allocated to treatment
with 3 mg melatonin or matching placebo for seven con-
secutive nights, beginning 2 nights prior to the surgery.
The contents of each capsule will be administered via a
nasogastric tube for those who are unable to swallow.
Outcomes
We will use a set of well-validated instruments and
scales to assess for the presence of delirium and measure
its severity, as well as to assess other outcomes of inter-
est for this study.
Establishing the presence of delirium
The CAM will be used to establish the presence of delir-
ium. The first assessment will take place in the pre-
assessment clinic or hospital ward prior to the surgery
(usually a week before but this can vary) and then daily,
beginning 1 day post surgery and continuing for up to
7 days or until discharged (whichever comes first). The
CAM was developed in 1988–1990 and is a widely used
and well-validated screening tool for delirium, with sen-
sitivity of 94 % (95 % CI 91–97 %) and specificity of
89 % (95 % CI 85–94 %) [37]. A trained research nurse
will rate the scale on the basis of a standardized inter-
view with the patient that includes a brief cognitive as-
sessment. Case notes and nursing staff reports will be
reviewed as part of the assessment. The diagnosis of de-
lirium will be confirmed in consultation with an experi-
enced psychogeriatrician (AHF or OPA). The CAM rates
nine areas (acuity, attention, thought organization, level
of consciousness, orientation, memory, perception, psy-
chomotor tempo and sleep), but delirium is only diag-
nosed when there is evidence of acute onset, inattention,
fluctuating mental state and either disorganized thinking
or disturbed consciousness. The CAM has been success-
fully adapted for use in the intensive care setting [38].
The rating of the CAM takes about 10 minutes to
complete.
Establishing the severity of delirium
The Memorial Delirium Assessment Scale (MDAS) [39]
will be used to assess the severity of delirium and will be
administered daily if delirium is present. The MDAS is a
4-point, 10-item (range 0–30) clinician-rated scale de-
signed to quantify the severity of delirium in a medically
ill patient population. It takes approximately 10 minutes
to complete.
Measuring morbidity and lifestyle
1. Alcohol abuse or dependency: the AUDIT is a 10-
item questionnaire designed to screen for excessive
drinking. It takes 2 minutes to complete, with scores
of 15 or greater indicating harmful alcohol use or
dependency [36]
2. Medical morbidities, medications and lifestyle: we
will collect information about demographics, lifestyle
(smoking, alcohol use, body mass index), common
medical conditions diagnosed by a doctor, and
medications used (including use of illicit substances).
This questionnaire takes approximately 5–10
minutes to complete
3. Details of surgery: we will record the type of surgery
and total length of surgical procedure including
duration on bypass (if applicable)
4. Medications: we will record participants’
medications on admission and discharge. We will
also record the use of all psychiatric medications
during hospitalization
5. Referral to mental health or geriatric services during
admission will be recorded
6. Length of stay (LOS): we will record total hospital
stay duration and intensive care unit (ICU) length of
stay in hours for participants discharged alive from
hospital
7. Destination post discharge: we will record
destination post discharge for all participants and,
for the purposes of analysis, will group them into
“discharge to usual place of residence” versus
“discharge to other places.” Participants who die
following cardiac surgery will form a separate group
8. Cognition: this will be measured with the TICS-m.
The TICS-m is a brief, widely used telephone
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assessment instrument with good reliability and validity
to screen for dementia and cognitive impairment in
older people [40]. It can be rated in person or by
telephone. It consists of 13 items measuring various
aspects of cognitive function yielding a total score of
50. Scores ≤27 indicate the presence of clinically
significant cognitive impairment. Cognitive function
will be measured at baseline, discharge and 3 months
after surgery. The TICS-m was chosen to allow us to
assess participants’ cognition 3 months after surgery in
the comfort of their own homes. We deliberately chose
this approach to reduce participant burden and
improve study retention. In addition, many Western
Australian patients live in country areas so that
in-person attendance would be difficult
9. Depressive and anxiety symptoms: we will measure
depressive and anxiety symptoms at baseline, discharge
and at 3 months with the Hospital Anxiety and
Depression Scale (HADS) [41]. This is a self-report
scale of 14 items in total that gives sub-scores for both
depression and anxiety
Participant timeline and recruitment
Table 1 shows the trial assessment schedule and Fig. 2
summarizes the recruitment and the flow of participants
in the trial. Participants will be approached in pre-
assessment clinics (all patients attend these a week or so
prior to the scheduled surgery) and general hospital wards
for those already hospitalized and awaiting surgery (i.e.,
semi-elective cases). Enrolled participants will be seen
daily following their surgery with the primary outcome of
interest being the difference in the incidence of delirium
between the two groups. The final hospital assessment will
occur on day 7 following surgery or the day of discharge
(whichever comes first). Participants will be followed up
one more time at 3 months after surgery to assess for the
presence of delirium and to measure cognitive function.
Sample size
The primary outcome of the proposed trial is the develop-
ment of delirium within 7 days of surgery. We based our
sample size on the trial of Al-Aama and colleagues [31].
They reported a 15.6 % absolute reduction (19.2 % versus
3.6 %, p < 0.02) in the incidence of delirium in their sam-
ple. Assuming a 15.6 % absolute risk reduction in our pa-
tients with a conservative 25 % incidence of delirium in
the control group and an incidence of 9.4 % in the inter-
vention group, we will require 91 participants per group
(182 participants in total) to detect a difference of this
magnitude with a power of 80 % and a two-sided alpha of
0.05. After allowing for a conservative loss to follow-up of
15 % [31], we calculated that we will need to recruit 210
participants (105 per group). A defined secondary out-
come for this trial is cognitive performance 1 week and
3 months after surgery. A study with 100 participants per
group at the 3-month follow-up will have 81 % power to
declare as significant between group difference of 2 points
in the change from baseline score of the TICS-m (1 versus
3 points, SD 5). A change of less than 2 points would be
of uncertain clinical significance.
Allocation, randomization, blinding and compliance
Participants will be randomized to treatment with mela-
tonin or placebo in a ratio of 1:1 according to a list of
Table 1 Summary of trial assessment schedule















Adverse events x x
CAM x x x x
MDAS x x (if
required)
x (if required) x (if
required)
TICS-m x x x
HADS x x x
AUDIT Alcohol Use Disorders Identification Test, CAM Confusion Assessment
Method, HADS Hospital Anxiety Depression Scale, LOS length of stay, MDAS
Memorial Delirium Assessment Scale, TICS-m Telephone Interview for
Cognitive Status-modified
Fig. 2 Summary of participant timelines. The figure summarizes the
enrollment procedure and time commitment for participants
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computer-generated random numbers in permuted
blocks ranging from 8 to 12. This strategy decreases the
risk of unblinding of participants in one particular block
if, for some reason, the group membership of one of its
members is disclosed. The list will be generated and
maintained by an independent biostatistician.
The pharmacy will dispense melatonin or placebo.
Melatonin and placebo will be administered as oral cap-
sules that have the same size, weight, color, texture and
taste. The active medication will consist of 3 mg mela-
tonin. These will be manufactured in batches every
12 months with 6-monthly stability testing performed
for weight, disintegration, impurities and appearance.
The pharmacy will be responsible for dispensing all
study medications, which will be included on the patient
medication chart as per usual hospital practice. Unblind-
ing will only occur once the final endpoint of interest is
collected from the last participant in the trial. Compli-
ance will be encouraged through a telephone call to each
participant 2 days prior to his or her scheduled surgery
date. Participants will be reminded to take their tablets
and will be asked to bring the remainder into hospital
for use following their surgery. Participants will be given
ten tablets to allow for the possibility of surgery being
postponed once they have commenced taking the trial
medication. We will record all incidences where partici-
pants take extra tablets beyond the scheduled seven.
Treatment adherence will be determined by the system-
atic review of medication charts upon discharge and by
pill count. Use of sedative/psychotropic medications out-
side of the study protocol will also be recorded.
Data collection and management
Data collection will be paper-based and subsequently en-
tered into a secure, password-protected database. Paper
files will be kept in a locked filing cabinet in the
principle investigator’s office and stored for a minimum
of 5 years following completion of the trial.
Statistical methods
We will analyze and store the data using reliable statis-
tical software (Stata, StataCorp, College Station, TX,
USA). Baseline data will be compared using descriptive
statistics, Student t tests for normally distributed con-
tinuous variables, the Mann-Whitney test for ordinal
variables and Pearson’s chi-square statistic for categor-
ical variables. The primary outcome analysis will be
intention-to-treat and will use multilevel logistic regres-
sion of panel data (xtlogit). This approach to the analysis
of the data allows for the inclusion of all available infor-
mation and for the investigation of interactions between
terms (such as intervention and time). A similar ap-
proach will be used to analyze other binary outcomes
(e.g., use of psychotropic medication). We will use
multilevel mixed models to investigate changes in scores
of the MDAS and TICS-m (continuous variables). All
probability tests will be two-tailed and will be declared
as significant when p < 0.05.
Data monitoring and safety
We will monitor adverse effects with a checklist of
symptoms commonly associated with experimental med-
ications, such as tremor, headaches, anxiety, insomnia
and gastrointestinal symptoms. The participants will be
asked about the emergence of any new symptoms since
the last assessment and how much they have been both-
ered by them: not at all, a little, quite a bit and ex-
tremely. The checklist will be completed prior to
enrollment and at discharge. The investigators will use
this to screen for any new symptoms that could be at-
tributed to the study medication. Melatonin is a natur-
ally occurring hormone and the incidence of serious
adverse events is expected to be low. An independent,
unblinded data monitoring committee, chaired by an in-
dependent academic biostatistician, will be established to
oversee the safety of participants in the trial. This com-
mittee will meet twice per year. Using statistical criteria
for acceptable deviations from the null hypothesis, the
committee will advise the investigators whether the re-
cruitment can continue or whether the study should be
terminated.
Ethics and dissemination
All participants will be required to provide written in-
formed consent prior to enrollment in the trial. The Hu-
man Research Ethics Committee of the Sir Charles
Gairdner Hospital, Perth, Western Australia has ap-
proved the study protocol. Results of the trial will be
widely disseminated in relevant literature and at leading
international and national conferences.
Discussion
Delirium is a major issue for the medical community
and is associated with universally poor outcomes for pa-
tients, their families and the health care system. Delir-
ium is particularly problematic in surgical populations
and may complicate up to 42 % of patients undergoing
major cardiac surgery. Identification and management of
sufferers is often complex and many individuals are
missed. Prevention of this common condition is, therefore,
essential. This trial will determine if melatonin is able to
reduce the incidence and duration of delirium following
cardiac surgery and also reduce the burden of other asso-
ciated factors such as cognitive decline, hospital length of
stay and anxiety and depressive symptoms.
The design of this trial has strengths and weaknesses
that merit comment. It has not yet been established what
dose of melatonin may be optimal for the prevention or
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treatment of delirium. The trials conducted to date
have utilized a variety of doses ranging from 0.5 to 5 mg
[30, 31, 33] and one that used 8 mg of the melatonin
agonist ramelteon [34]. The trial by de Jonghe and col-
leagues showed the 3-mg dose used in the study to be
both well-tolerated and safe [33], as did another trial in
tracheostomized intensive care patients that additionally
showed that 3 mg melatonin successfully increased blood
levels 1000-fold [42]. A number of other trials have con-
firmed the safety and tolerability of a 3-mg dose in popu-
lations with varying medical morbidities and age ranges
[43–46]. We will exclude participants with cognitive im-
pairment, given the possible difficulties with consent and
the ability to follow the trial protocol. We understand,
however, that this may reduce the overall incidence of de-
lirium in our sample, as pre-existing cognitive impairment
is a strong predictor of delirium.
This trial will be restricted to adults aged 50 and older
because the incidence of delirium is higher in later life.
We will also exclude participants undergoing emergency
surgery because of the ethical requirements for recruit-
ment and informed consent. The study will be limited to
participants with sufficient English skills to be able to
participate in the assessments and complete the study
questionnaires. All of these factors could potentially de-
crease the generalizability of our findings.
These limitations should be considered in light of a
number of strengths of this trial. We will be recruiting
from a well-defined population at high risk of developing
delirium. The trial has well-defined outcomes and has
been adequately powered. We will investigate the impact
of melatonin on delirium in the immediate postoperative
period and will also be able to study its clinical effects
3 months later.
Melatonin could prove to be a simple, cost-effective
and safe intervention for patients at high risk of delir-
ium. The results of this Consolidated Standards of
Reporting Trials (CONSORT) compliant trial, if positive,
could contribute to change the way people at high risk
of delirium are managed in clinical practice.
Trial status
The Healthy Heart-Mind trial has not yet commenced
recruitment.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*.
(DOC 114 kb)
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